New guest commentary in BioCentury by Gigi Hirsch & Jane Barlow seeds a series of discussions now underway to shape priorities for the “Next Big Thing” in the Center for … Read More
Payer and developer perspectives on alternative payment models
Expert Review of Pharmacoeconomics & Outcomes Research, Volume 24, 2024 – Issue 2Moradian, R., Meshesha, T., Trusheim, M., & Barlow, J. F. The paper reports the results of a survey … Read More
Medicaid best price reforms to enable innovative payment models for cell and gene therapies
Expert Review of Pharmacoeconomics & Outcomes Research, 23(2), 191–203.Quinn, C., Ciarametaro, M., Sils, B., Phares, S., & Trusheim, M. Cell and gene therapies promise durable benefits but face financial challenges … Read More
How can self-insured employers prepare for the portfolio impact of highcost gene therapies coming to market?
Self-insured employers (SIEs) currently rely on traditional stop-loss insurance to protect against unexpected high-cost claims, including those for cell and gene therapies. Given that current approvals are in rare diseases, … Read More
Broadly Engaged Team Science Comes to Life in a Design Lab
The objective of broadly engaged team science is to bring a diverse group of stakeholders into a project early and continue to include their expertise throughout to inform and propel … Read More
Precision for Whom? Partnering with patients to ensure that Precision Medicine targets what matters
Despite decades of growth and adaptation in patient engagement, knowing or being able to find guidance for whichmodel or approach will be most impactful in which healthcare or research context … Read More
The resource navigation challenges for patients and caregivers
Share the researchWhile the problem of finding system-wide, implementable precision financing models for curative and durable therapies involves all stakeholders, patients and caregivers are directly affected by many different elements … Read More
Downstream Innovation Part II
December 2019 marked the transition from the LEAPS two-year design and feasibility assessment phase to the rollout of the rheumatoid arthritis in Massachusetts (RA MA) Pilot. Some important themes surrounding … Read More
Impact of FDA Guidelines on Communication between Developers and Payers on Metrics in Performance-Based Agreements
The FDA regulates communications from pharmaceutical developers to ensure that statements about products are appropriately supported by evidence. In this Research Brief, we explore the possible impacts of these regulations … Read More
Precision Financing challenges for solid tumor adoptive T-cell therapies
Durable gene and cell therapies represent a unique challenge to the US healthcare insurer/payer landscape, given the one-time treatment and associated high upfront cost but potentially durable outcomes. Previous research … Read More